<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:department>Department of Cellular and Molecular Sci</gtr:department><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/EC34689C-9D83-4134-BA5E-64E341F44033"><gtr:id>EC34689C-9D83-4134-BA5E-64E341F44033</gtr:id><gtr:firstName>Charles</gtr:firstName><gtr:otherNames>Johnathan</gtr:otherNames><gtr:surname>Woodrow</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G108%2F667"><gtr:id>F131F12F-BB20-43C3-8895-8831BEF22D4F</gtr:id><gtr:title>Mechanisms and consequences of the interaction between artemisinins and Ca2+-ATPases of Plasmodium spp.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G108/667</gtr:grantReference><gtr:abstractText>Malaria causes 1-2 million deaths each year, and in many areas malaria parasites have become resistant to most antimalarial drugs. A group of compounds originally developed in China, the artemisinins, represents our best available hope against resistant malaria and is about to be widely deployed in Africa. Despite years of study, the mechanism of action of artemisinins remains unclear. Recent work in the sponsor?s laboratory has shown that artemisinins inhibit a membrane protein which probably pumps calcium between cell compartments. This Fellowship aims to study in great detail how artemisinins interfere with this calcium pump. The applicant has worked on membrane pumps and other transporters in his PhD, and during this Fellowship will expand his experience to include studies using models of malaria infection. Understanding how artemisinins kill malaria parasites will help in monitoring for the development of drug resistance as well as designing more effective antimalarial drugs.</gtr:abstractText><gtr:technicalSummary>Aim: To understand the molecular basis of interaction between artemisinin and PfATP6, and to study the cellular consequences of artemisinin action

Design: Year 1 will be spent at St. George?s, beginning with a thorough analysis of PfATP6 binding residues which mediate artemisinin sensitivity, using a site-directed mutagenesis approach combined with functional assay in the heterologous Xenopus oocyte system. The physicochemical nature of the artemisinin-PfATP6 interaction will be explored. Constructs for subsequent P. berghei studies will be generated.

A period of 12-18 months in years 2 and 3 will be spent at Imperial College. Data from heterologous expression studies will be used to design appropriate transfection experiments using P. berghei. This period of time will also allow the applicant to use a novel calcium-detection system to determine the downstream effects of artemisinins on calcium physiology. 

Scientific and medical opportunities: As a clinician with an interest in clinical aspects of malaria, the opportunity to explore the mechanism of action (and therefore resistance) of our most important antimalarial is of enormous interest. In his PhD thesis the applicant characterised the P. falciparum hexose transporter, showing that it represented an excellent target for drug discovery projects. This Fellowship takes a different approach, working with a known antimalarial to discover its mode of action at the most basic molecular level. St. George?s has a proven track record in studying drug resistance, and a bank of patient samples to test. However, it is also important to apply knowledge gained from these studies to the cellular context, a process which should be achievable during the time spent at Imperial College. A period of up to 18 months at Imperial College will be necessary to take full advantage of the experimental and training aspects of this component of the work. There are no significant financial implications of this extended periodthe second centre.</gtr:technicalSummary><gtr:fund><gtr:end>2010-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>703273</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>High throughput method for improving studies on mechanisms of resistance</gtr:description><gtr:id>21B15670-81F8-4F6B-A3F0-5E2F19CE5E7E</gtr:id><gtr:impact>Improved understanding of K13 mutations in African malaria parasites</gtr:impact><gtr:outcomeId>RgiYyhDWcnv</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Evolutionary analysis</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Specific primary antibodies</gtr:description><gtr:id>892FA8D0-E45A-47EF-B321-50BE9E842359</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>GndaSfXtV8c</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Antibodies</gtr:title><gtr:type>Antibody</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>84E32901-2A2D-434E-824D-C6B26C1198FF</gtr:id><gtr:title>Protein-based signatures of functional evolution in Plasmodium falciparum.</gtr:title><gtr:parentPublicationTitle>BMC evolutionary biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4861f0d3eaec016b7febb523e56f1a6e"><gtr:id>4861f0d3eaec016b7febb523e56f1a6e</gtr:id><gtr:otherNames>Gardner KB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1471-2148</gtr:issn><gtr:outcomeId>cMD5ZLXZCuC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C5485F2-CAA7-45E9-88DD-BD90CDF4BDD7</gtr:id><gtr:title>Identification, expression and characterisation of a Babesia bovis hexose transporter.</gtr:title><gtr:parentPublicationTitle>Molecular and biochemical parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f9ba5c891b3462f23e5f79f4a418731"><gtr:id>3f9ba5c891b3462f23e5f79f4a418731</gtr:id><gtr:otherNames>Derbyshire ET</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0166-6851</gtr:issn><gtr:outcomeId>be7ynDmQ66j</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7723CC9B-60A0-46D1-B602-CB6B1D6E97B9</gtr:id><gtr:title>Artemisinin Antimalarials: Preserving the &amp;quot;Magic Bullet&amp;quot;</gtr:title><gtr:parentPublicationTitle>Drug development research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8cd85e47a5f1abf37e1441d803b435d6"><gtr:id>8cd85e47a5f1abf37e1441d803b435d6</gtr:id><gtr:otherNames>Maude RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0272-4391</gtr:issn><gtr:outcomeId>DMEmqM7T8fm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3C4BE89-6B99-4D16-A7FE-BF0BFEAD823A</gtr:id><gtr:title>Mechanisms of artemisinin action and resistance: wider focus is needed.</gtr:title><gtr:parentPublicationTitle>Trends in parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d898359c525b6b59ec9cb230a7a7c545"><gtr:id>d898359c525b6b59ec9cb230a7a7c545</gtr:id><gtr:otherNames>Woodrow CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1471-4922</gtr:issn><gtr:outcomeId>54633bf691c217.12744612</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF19B042-E6FB-424A-823A-D3909148F175</gtr:id><gtr:title>Questions over high frequency of mutant PfATP6 haplotypes in traveller isolates.</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d898359c525b6b59ec9cb230a7a7c545"><gtr:id>d898359c525b6b59ec9cb230a7a7c545</gtr:id><gtr:otherNames>Woodrow CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn><gtr:outcomeId>54633bf62e1012.68363494</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4870C6F7-A95C-481B-A6EB-9131EEC3A6C2</gtr:id><gtr:title>Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial.</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d4579b9f9780168ff704cd88c8c30e8"><gtr:id>1d4579b9f9780168ff704cd88c8c30e8</gtr:id><gtr:otherNames>Awab GR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn><gtr:outcomeId>L5gCvui38xG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B174F29C-CA23-4C97-9D7D-708007EB5E92</gtr:id><gtr:title>Plasmodium falciparum ATP6 not under selection during introduction of artemisinin combination therapy in Peru.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d898359c525b6b59ec9cb230a7a7c545"><gtr:id>d898359c525b6b59ec9cb230a7a7c545</gtr:id><gtr:otherNames>Woodrow CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>54633bf65871c4.84035659</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D73AA86-3CF2-4499-B835-4EDBA4472EEE</gtr:id><gtr:title>Computational analysis of binding between malarial dihydrofolate reductases and anti-folates.</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77ebd4d7ea6789e346551b065c7c8118"><gtr:id>77ebd4d7ea6789e346551b065c7c8118</gtr:id><gtr:otherNames>Choowongkomon K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn><gtr:outcomeId>BybTN2gVKsR</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G108/667</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>